product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD279 (PD-1) Monoclonal Antibody (MIH4), eBioscience
catalog :
14-9969-82
quantity :
100 µg
price :
US 200
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
MIH4
reactivity :
human, mouse
application :
western blot, immunohistochemistry, flow cytometry, immunohistochemistry - frozen section, blocking or activating experiments
more info or order :
Invitrogen product webpage
citations: 66
Published Application/Species/Sample/DilutionReference
  • flow cytometry; human; loading ...; fig 4b
Liu G, Yu Y, Feng F, Zhu P, Zhang H, Zhang D, et al. Human CD8+CD28- T suppressor cells expanded by common gamma chain (γc) cytokines retain steady allospecific suppressive capacity in vivo. BMC Immunol. 2020;21:23 pubmed publisher
  • flow cytometry; human; loading ...; fig 7
Moreno Cubero E, Subira D, Sanz de Villalobos E, Parra Cid T, Madejon A, Miquel J, et al. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity. J Virol. 2018;92: pubmed publisher
  • flow cytometry; human; loading ...; fig 6a
Komdeur F, Wouters M, Workel H, Tijans A, Terwindt A, Brunekreeft K, et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget. 2016;7:75130-75144 pubmed publisher
  • immunohistochemistry - frozen section; human; 1:50; fig 2
Gulati N, Suárez Fariñas M, Correa Da Rosa J, Krueger J. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res. 2015;4:149 pubmed publisher
  • flow cytometry; human; fig 1
Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher
  • flow cytometry; human; 1.6:100
Gros A, Robbins P, Yao X, Li Y, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8? tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124:2246-59 pubmed publisher
  • immunohistochemistry - frozen section; human; fig 1
Raptopoulou A, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62:1870-80 pubmed publisher
  • blocking or activating experiments; human; fig 6
  • flow cytometry; human; fig 4
Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009;183:4984-93 pubmed publisher
Islam S, Maeda T, Tamaoki N, Good M, Kishton R, Paria B, et al. Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells. Cancer Res Commun. 2023;3:917-932 pubmed publisher
Kotetsu Y, Yanagihara T, Suzuki K, Ando H, Eto D, Hata K, et al. Imaging Changes and Immune-Checkpoint Expression on T Cells in Bronchoalveolar Lavage Fluid from Patients with Pulmonary Sarcoidosis. Biomedicines. 2021;9: pubmed publisher
Zhan T, Gao X, Wang G, Li F, Shen J, Lu C, et al. Construction of Novel lncRNA-miRNA-mRNA Network Associated With Recurrence and Identification of Immune-Related Potential Regulatory Axis in Hepatocellular Carcinoma. Front Oncol. 2021;11:626663 pubmed publisher
Zheng G, Guo Z, Li W, Xi W, Zuo B, Zhang R, et al. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther. 2021;6:236 pubmed publisher
YEKU O, Rao T, Laster I, Kononenko A, Purdon T, Wang P, et al. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition. Front Immunol. 2021;12:663379 pubmed publisher
Xu X, Hou B, Fulzele A, Masubuchi T, Zhao Y, Wu Z, et al. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. J Cell Biol. 2020;219: pubmed publisher
Dötzer K, Schlüter F, Schoenberg M, Bazhin A, von Koch F, Schnelzer A, et al. Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. Cancers (Basel). 2019;11: pubmed publisher
Yang W, Lee K, Srivastava R, Kuo F, Krishna C, Chowell D, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019;25:767-775 pubmed publisher
Zhao Y, Harrison D, Song Y, Ji J, Huang J, Hui E. Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Rep. 2018;24:379-390.e6 pubmed publisher
Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018;215:985-997 pubmed publisher
Gong Q, Zhu Y, Pang N, Ai H, Gong X, La X, et al. Increased levels of CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells, and associated factors Bcl-6, CXCR5, IL-21 and IL-6 contribute to repeated implantation failure. Exp Ther Med. 2017;14:5931-5941 pubmed publisher
Gu Trantien C, Migliori E, Buisseret L, de Wind A, Brohée S, Garaud S, et al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight. 2017;2: pubmed publisher
Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
Cheng L, Tang X, Liu L, Peng J, Nishiura K, Cheung A, et al. Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. MAbs. 2015;7:620-9 pubmed publisher
Wolchinsky R, Hod Marco M, Oved K, Shen Orr S, Bendall S, Nolan G, et al. Antigen-dependent integration of opposing proximal TCR-signaling cascades determines the functional fate of T lymphocytes. J Immunol. 2014;192:2109-19 pubmed publisher
Pen J, Keersmaecker B, Heirman C, Corthals J, Liechtenstein T, Escors D, et al. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014;21:262-71 pubmed publisher
Baglio F, Saresella M, Preti M, Cabinio M, Griffanti L, Marventano I, et al. Neuroinflammation and brain functional disconnection in Alzheimer's disease. Front Aging Neurosci. 2013;5:81 pubmed publisher
Weber J, Kudchadkar R, Yu B, Gallenstein D, Horak C, Inzunza H, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31:4311-8 pubmed publisher
Turcotte S, Gros A, Hogan K, Tran E, Hinrichs C, Wunderlich J, et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol. 2013;191:2217-25 pubmed publisher
Liu X, Gao N, Li M, Xu D, Hou Y, Wang Q, et al. Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS ONE. 2013;8:e64531 pubmed publisher
Sellebjerg F, Krakauer M, Khademi M, Olsson T, Sørensen P. FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis. Clin Exp Immunol. 2012;170:149-55 pubmed publisher
Khalid M, Yu H, Sauter D, Usmani S, Schmökel J, Feldman J, et al. Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection. J Virol. 2012;86:4906-20 pubmed publisher
Kotturi M, Swann J, Peters B, Arlehamn C, Sidney J, Kolla R, et al. Human CD8? and CD4? T cell memory to lymphocytic choriomeningitis virus infection. J Virol. 2011;85:11770-80 pubmed publisher
Kuntz M, Goldacker S, Blum H, Pircher H, Stampf S, Peter H, et al. Analysis of bulk and virus-specific CD8+ T cells reveals advanced differentiation of CD8+ T cells in patients with common variable immunodeficiency. Clin Immunol. 2011;141:177-86 pubmed publisher
Kim Y, Park S, Broxmeyer H. Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction. J Immunol. 2011;187:2291-301 pubmed publisher
Andorsky D, Yamada R, Said J, Pinkus G, Betting D, Timmerman J. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232-44 pubmed publisher
Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Farina E, et al. A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease. Neurobiol Aging. 2012;33:624.e11-22 pubmed publisher
Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011;15:R70 pubmed publisher
Chung J, Shiue L, Duvic M, Pandya A, Cruz P, Ariizumi K. Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood. 2011;117:3382-90 pubmed publisher
Cabezón R, Sintes J, Llinàs L, Benitez Ribas D. Analysis of HLDA9 mAbs on plasmacytoid dendritic cells. Immunol Lett. 2011;134:167-73 pubmed publisher
Plege A, Borns K, Beer L, Baars W, Klempnauer J, Schwinzer R. Downregulation of cytolytic activity of human effector cells by transgenic expression of human PD-ligand-1 on porcine target cells. Transpl Int. 2010;23:1293-300 pubmed publisher
Benson D, Bakan C, Mishra A, Hofmeister C, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286-94 pubmed publisher
Chen Y, Hu Z, Wang Q, Ge Y, Bai L, Wang X, et al. Generation and characterization of four novel monoclonal antibodies against human programmed death-1 molecule. Hybridoma (Larchmt). 2010;29:153-60 pubmed publisher
Zhang L, Bertucci A, Ramsey Goldman R, Burt R, Datta S. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol. 2009;183:6346-58 pubmed publisher
van Velzen M, Laman J, Kleinjan A, Poot A, Osterhaus A, Verjans G. Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype. J Immunol. 2009;183:2456-61 pubmed publisher
Zhang Z, Jin B, Zhang J, Xu B, Wang H, Shi M, et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol. 2009;50:1163-73 pubmed publisher
Takahashi N, Matsumoto K, Saito H, Nanki T, Miyasaka N, Kobata T, et al. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J Immunol. 2009;182:5515-27 pubmed publisher
Kinter A, Godbout E, McNally J, Sereti I, Roby G, O Shea M, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008;181:6738-46 pubmed
Kuttruff S, Koch S, Kelp A, Pawelec G, Rammensee H, Steinle A. NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood. 2009;113:358-69 pubmed publisher
Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009;23:375-82 pubmed publisher
Lages C, Suffia I, Velilla P, Huang B, Warshaw G, Hildeman D, et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol. 2008;181:1835-48 pubmed
Saresella M, Marventano I, Longhi R, Lissoni F, Trabattoni D, Mendozzi L, et al. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J. 2008;22:3500-8 pubmed publisher
Taglauer E, Trikhacheva A, Slusser J, Petroff M. Expression and function of PDCD1 at the human maternal-fetal interface. Biol Reprod. 2008;79:562-9 pubmed publisher
Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008;8:57 pubmed publisher
Chen L, Zhang Z, Chen W, Zhang Z, Li Y, Shi M, et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol. 2007;178:6634-41 pubmed
Thompson R, Dong H, Lohse C, Leibovich B, Blute M, Cheville J, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757-61 pubmed
Hamdi H, Godot V, Maillot M, Prejean M, Cohen N, Krzysiek R, et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood. 2007;110:211-9 pubmed
Zhang J, Zhang Z, Wang X, Fu J, Yao J, Jiao Y, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood. 2007;109:4671-8 pubmed
Carter L, Leach M, Azoitei M, Cui J, Pelker J, Jussif J, et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2007;182:124-34 pubmed
Krakauer M, Sorensen P, Sellebjerg F. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol. 2006;181:157-64 pubmed
Otsuki N, Kamimura Y, Hashiguchi M, Azuma M. Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. Biochem Biophys Res Commun. 2006;344:1121-7 pubmed
Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 2003;171:4156-63 pubmed
Hatachi S, Iwai Y, Kawano S, Morinobu S, Kobayashi M, Koshiba M, et al. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol. 2003;30:1410-9 pubmed
Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, Honjo T. Microanatomical localization of PD-1 in human tonsils. Immunol Lett. 2002;83:215-20 pubmed
Latchman Y, Wood C, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261-8 pubmed
Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-34 pubmed
Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol. 1996;8:773-80 pubmed
Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765-72 pubmed
product information
Product Type :
Antibody
Product Name :
CD279 (PD-1) Monoclonal Antibody (MIH4), eBioscience
Catalog # :
14-9969-82
Quantity :
100 µg
Price :
US 200
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Mouse
Reactivity :
Human, Mouse
Applications :
Flow Cytometry: 1 µg/test, Immunohistochemistry (Frozen): Assay-Dependent, Western Blot: 0.5 µg/mL
Species :
Human, Mouse
Clone :
MIH4
Isotype :
IgG1, kappa
Storage :
4° C
Description :
Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 1 µg/test, Immunohistochemistry (Frozen): Assay-Dependent, Western Blot: 0.5 µg/mL
Aliases :
CD279; EGK_05005; hPD1; hPD-1; hPD-l; hSLE1; Ly101; mPD-1; PD1; PD-1; Pdc1; Pdcd1; programmed cell death 1; programmed cell death 1 protein; programmed cell death protein 1; programmed cell death protein 1-like; programmed death 1; Protein PD1; protein PD-1; sCD279; SLEB2; soluble CD279; systemic lupus erythematosus susceptibility 2
more info or order :
Invitrogen product webpage
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA